Boston Scientific AGENT Drug-Coated Balloon Demonstrates Sup

Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB 

Related Keywords

Boston , Massachusetts , United States , Japan , Robertw Yeh , Janarthanan Sathananthan , Drug Administration , Boston Scientific Corporation On , Boston Scientific , Harvard Medical School , Cardiovascular Research Foundation , Beth Israel Deaconess Medical Center , Boston Scientific Corporation , Coated Balloon , Transcatheter Cardiovascular Therapeutics , Cardiovascular Research , Katz Silver Family Professor , Harvard Medical , Interventional Cardiology Therapies , Breakthrough Device ,